A novel multiple marker bioassay utilizing HE4 and CA125 for the prediction of ovarian cancer in patients with a pelvic mass

Gynecologic Oncology

Volumn 112, Issue 1, 2009, Pages 40-46

  Moore, Richard G ^a   McMeekin, D Scott ^b   Brown, Amy K ^c   DiSilvestro, Paul ^a   Miller, M Craig ^d   Allard, W Jeffrey ^d   Gajewski, Walter ^e   Kurman, Robert ^f   Bast Jr , Robert C ^g   Skates, Steven J ^h  

^a BROWN UNIVERSITY   (United States)

^b UNIVERSITY OF OKLAHOMA HEALTH SCIENCES CENTER   (United States)

^c HARTFORD HOSPITAL   (United States)

^d FUJIREBIO INC   (Japan)

^e Coastal Health ^*  (United States)

^f JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^h MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

CA125; HE4; Ovarian cancer; Ovarian cancer detection; Pelvic mass; Tumor marker

Indexed keywords

CA 125 ANTIGEN; HE4 PROTEIN; PROTEIN; TUMOR MARKER; UNCLASSIFIED DRUG;

ADULT; AGED; ALGORITHM; ARTICLE; BIOASSAY; CANCER DIAGNOSIS; CANCER PATIENT; CANCER RISK; CANCER STAGING; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED STUDY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MULTICENTER STUDY; OVARY CANCER; PELVIS; POSTMENOPAUSE; PREDICTION; PREMENOPAUSE; PRIORITY JOURNAL; PROSPECTIVE STUDY; SENSITIVITY AND SPECIFICITY;

ADULT; AGED; AGED, 80 AND OVER; ALGORITHMS; CA-125 ANTIGEN; EPIDIDYMAL SECRETORY PROTEINS; FEMALE; HUMANS; LOGISTIC MODELS; MIDDLE AGED; OVARIAN NEOPLASMS; PELVIC NEOPLASMS; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; TUMOR MARKERS, BIOLOGICAL;

EID: 57649088474     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2008.08.031     Document Type: Article

References (24)

1. Curtin J.P. Management of the adnexal mass. Gynecol. Oncol. 55 3 Pt 2 (1994) S42-S46
2. Carney M.E., Lancaster J.M., Ford C., Tsodikov A., and Wiggins C.L. A population-based study of patterns of care for ovarian cancer: who is seen by a gynecologic oncologist and who is not?. Gynecol. Oncol. 84 1 (2002) 36-42
3. McGowan L., Lesher L.P., Norris H.J., and Barnett M. Misstaging of ovarian cancer. Obstet. Gynecol. 65 4 (1985) 568-572
4. Paulsen T., Kjaerheim K., Kaern J., Tretli S., and Trope C. Improved short-term survival for advanced ovarian, tubal, and peritoneal cancer patients operated at teaching hospitals. Int. J. Gynecol. Cancer 16 Suppl 1 (2006) 11-17
5. Engelen M.J., Kos H.E., Willemse P.H., Aalders J.G., de Vries E.G., Schaapveld M., et al. Surgery by consultant gynecologic oncologists improves survival in patients with ovarian carcinoma. Cancer 106 3 (2006) 589-598
6. Earle C.C., Schrag D., Neville B.A., Yabroff K.R., Topor M., Fahey A., et al. Effect of surgeon specialty on processes of care and outcomes for ovarian cancer patients. J. Natl. Cancer Inst. 98 3 (2006) 172-180
7. Giede K.C., Kieser K., Dodge J., and Rosen B. Who should operate on patients with ovarian cancer? An evidence-based review. Gynecol. Oncol. 99 2 (2005) 447-461
8. Maggino T., Gadducci A., D'Addario V., Pecorelli S., Lissoni A., Stella M., et al. Prospective multicenter study on CA 125 in postmenopausal pelvic masses. Gynecol. Oncol. 54 2 (1994) 117-123
9. Bast Jr. R.C., Klug T.L., St John E., Jenison E., Niloff J.M., Lazarus H., et al. A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer. N. Engl. J. Med. 309 15 (1983) 883-887
10. Jacobs I., and Bast Jr. R.C. The CA 125 tumour-associated antigen: a review of the literature. Hum. Reprod. 4 1 (1989) 1-12
11. Moore R.G., Brown A.K., Miller M.C., Skates S., Allard W.J., Verch T., et al. The use of multiple novel tumor biomarkers for the detection of ovarian carcinoma in patients with a pelvic mass. Gynecol. Oncol. 108 (2007) 402-408
12. Pickle L.W., Hao Y., Jemal A., Zou Z., Tiwari R.C., Ward E., et al. A new method of estimating United States and state-level cancer incidence counts for the current calendar year. CA Cancer J. Clin. 57 1 (2007) 30-42
13. Hoskins W.J., McGuire W.P., Brady M.F., Homesley H.D., Creasman W.T., Berman M., et al. The effect of diameter of largest residual disease on survival after primary cytoreductive surgery in patients with suboptimal residual epithelial ovarian carcinoma. Am. J. Obstet. Gynecol. 170 4 (1994) 974-979
14. Bristow R.E., Montz F.J., Lagasse L.D., Leuchter R.S., and Karlan B.Y. Survival impact of surgical cytoreduction in stage IV epithelial ovarian cancer. Gynecol. Oncol. 72 3 (1999) 278-287
15. Curtin J.P., Malik R., Venkatraman E.S., Barakat R.R., and Hoskins W.J. Stage IV ovarian cancer: impact of surgical debulking. Gynecol. Oncol. 64 1 (1997) 9-12
16. Young R.C., Decker D.G., Wharton J.T., Piver M.S., Sindelar W.F., Edwards B.K., et al. Staging laparotomy in early ovarian cancer. JAMA 250 22 (1983) 3072-3076
17. Olaitan A., Weeks J., Mocroft A., Smith J., Howe K., and Murdoch J. The surgical management of women with ovarian cancer in the south west of England. Br. J. Cancer 85 12 (2001) 1824-1830
18. McGowan L., Lesher L.P., Norris H.J., and Barnett M. Misstaging of ovarian cancer. Obstet. Gynecol. 65 4 (1985) 568-572
19. Bouchard D., Morisset D., Bourbonnais Y., and Tremblay G.M. Proteins with whey-acidic-protein motifs and cancer. Lancet Oncol. 7 2 (2006) 167-174
20. Bingle L., Cross S.S., High A.S., Wallace W.A., Rassl D., Yuan G., et al. WFDC2 (HE4): a potential role in the innate immunity of the oral cavity and respiratory tract and the development of adenocarcinomas of the lung. Respir. Res. 7 (2006) 61
21. Drapkin R., von Horsten H.H., Lin Y., Mok S.C., Crum C.P., Welch W.R., et al. Human epididymis protein 4 (HE4) is a secreted glycoprotein that is overexpressed by serous and endometrioid ovarian carcinomas. Cancer Res. 65 6 (2005) 2162-2169
22. Hellstrom I., Raycraft J., Hayden-Ledbetter M., Ledbetter J.A., Schummer M., McIntosh M., et al. The HE4 (WFDC2) protein is a biomarker for ovarian carcinoma. Cancer Res. 63 13 (2003) 3695-3700
23. Jacobs I., Oram D., Fairbanks J., Turner J., Frost C., and Grudzinskas J.G. A risk of malignancy index incorporating CA 125, ultrasound and menopausal status for the accurate preoperative diagnosis of ovarian cancer. Br. J. Obstet. Gynaecol. 97 10 (1990) 922-929
24. Bailey J., Tailor A., Naik R., Lopes A., Godfrey K., Hatem H.M., et al. Risk of malignancy index for referral of ovarian cancer cases to a tertiary center: does it identify the correct cases?. Int. J. Gynecol. Cancer 16 Suppl 1 (2006) 30-34